Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Thermo Fisher Scientific (TMO)

NYSE: TMO · Diagnostics & Research · Waltham, MA

Our rating: Neutral

Neutral reaffirmed at $682.65, moderate conviction, November 2, 2026.

Breaks if: Would turn Positive if annual revenue growth reaches 7% or above in the next reported fiscal year, signaling that end-market recovery — biotech funding and pharma capital spending — has genuinely arrived and given the premium multiple something to lean on. Would turn Cautious if free cash flow falls below $5.5B or annual revenue growth decelerates below 2% in the next reported year; at that point 38.5x earnings would rest on reputation rather than trajectory, and the current price would be difficult to defend on any near-term earnings path.

Key figures

Market value$248.1B
Revenue, last 12 months$47.4B
Net income, last 12 months$7.1B
Free cash flow, last 12 months$7.6B
Price to earnings35.1×
Free cash flow yield3.1%
Dividend yield0.3%
Operating margin17.9%
Return on equity13.4%
Beta to the S&P 5000.74
Volatility, annualized29.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 26, 2026$12.1B9.1%$4.64$2.1B
June 27, 2026$12.0B10.5%$4.68$1.7B
March 28, 2026$11.0B6.2%$4.43$816M
December 31, 2025$12.2B7.2%$5.21$3.0B
September 27, 2025$11.1B4.9%$4.27$1.8B
June 28, 2025$10.9B3.0%$4.28$1.1B
March 29, 2025$10.4B0.2%$3.98$361M
December 31, 2024$11.4B4.7%$4.78$2.8B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

15 ledger entries and 37 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.